Clinical Trial Update: Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia [Phase 3]

View source ↗

Summary

Phase 3 trial of IV ravulizumab in COVID-19 severe pneumonia was terminated; results posted but no ongoing study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Pneumonia Viral
• Respiratory Distress Syndrome

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: COVID-19 Severe Pneumonia, Acute Lung Injury | Phase 3 | Status: TERMINATED | Results posted: 2022-05-24